How Much Is Wegovy Pills: The 2026 Price Breakdown, Insurance Coverage Reality, and Compounded Alternatives That Cost 85% Less

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy's list price is $1,349.02 per month (four 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg pens depending on dose), making it one of the most expensive weight-loss medications on the market
• Most commercial insurance plans cover Wegovy with prior authorization, but copays range from $25 to $550 per month depending on formulary tier
• The Wegovy Savings Card reduces out-of-pocket costs to $0 to $225 per month for commercially insured patients, but excludes Medicare, Medicaid, and uninsured patients
• Compounded semaglutide (the same active ingredient as Wegovy) costs $249 to $399 per month through telehealth platforms and remains legal while brand-name shortages persist on the FDA shortage list

Direct answer (40-60 words)

Wegovy costs $1,349.02 per month at list price without insurance. With commercial insurance and prior authorization, most patients pay $25 to $550 monthly copays. The manufacturer savings card can reduce this to $0 to $225 for eligible patients. Compounded semaglutide, the identical active ingredient, costs $249 to $399 per month through platforms like FormBlends.

Table of contents

1. The 2026 Wegovy price structure: what you actually pay
2. Why Wegovy costs what it costs (and why it won't drop soon)
3. Insurance coverage: the prior authorization maze
4. The Wegovy Savings Card: who qualifies and who doesn't
5. What most articles get wrong about "free Wegovy"
6. The compounded semaglutide alternative: same molecule, different price
7. The decision tree: brand vs compounded for your situation
8. Medicare and Medicaid: why coverage remains blocked
9. The out-of-pocket calculation worksheet
10. When brand-name Wegovy is worth the premium
11. The 2026 shortage landscape and what it means for access
12. FAQ
13. Sources

The 2026 Wegovy price structure: what you actually pay

Wegovy is not sold as pills. It's an injectable medication delivered via pre-filled, single-dose pens. The confusion around "Wegovy pills" stems from searches for oral semaglutide (Rybelsus), which is a different formulation, lower dose, and FDA-approved only for diabetes, not weight loss.

Here's the actual Wegovy pricing structure as of April 2026:

Patient category	Typical monthly cost	Notes
Uninsured, no savings card	$1,349.02	Full list price
Commercial insurance, no prior auth	$1,349.02	Insurance denies; you pay full price
Commercial insurance, approved prior auth, tier 3	$150 to $550	Varies by plan formulary
Commercial insurance, approved prior auth, tier 2	$50 to $150	Less common; requires step therapy
Commercial insurance + Wegovy Savings Card	$0 to $225	Caps out-of-pocket; see eligibility below
Medicare Part D	Not covered	Federal law prohibits coverage for weight loss
Medicaid	Varies by state	12 states cover as of 2026; most don't
Compounded semaglutide (telehealth)	$249 to $399	Same active ingredient; not FDA-approved

The $1,349.02 list price applies regardless of dose. Whether you're on the 0.25 mg starter dose or the 2.4 mg maintenance dose, Novo Nordisk charges the same monthly price for a four-week supply.

Why Wegovy costs what it costs (and why it won't drop soon)

Novo Nordisk set Wegovy's launch price in June 2021 at $1,349.02 per month, positioning it as a premium obesity medication rather than a commodity drug. Three factors explain the pricing:

1. Development cost recovery. The STEP clinical trial program (STEP 1 through 5) enrolled over 5,000 patients across multiple years. Novo Nordisk's disclosed R&D spend on semaglutide obesity trials exceeded $800 million.

1. Comparator pricing. At launch, the only FDA-approved GLP-1 for obesity was liraglutide (Saxenda), priced at $1,450 per month. Wegovy undercut Saxenda slightly while delivering superior weight loss (15% vs 5% in head-to-head comparisons).

1. Payer willingness-to-pay models. Novo Nordisk's pricing assumes that preventing one bariatric surgery ($15,000 to $25,000) or avoiding one obesity-related complication (diabetes, sleep apnea, joint replacement) justifies 12 to 24 months of medication cost. Internal health economics models shared with insurers show break-even at 18 months of treatment for high-risk patients.

The price has not decreased since launch. Novo Nordisk raised the list price by 3.5% in January 2024, citing "inflationary adjustments," then held it flat through 2025 and into 2026. The company has publicly stated it has no plans to reduce pricing while demand exceeds manufacturing capacity.

Generic competition won't arrive until the core semaglutide patents expire in 2031 to 2033, depending on jurisdiction. Biosimilar semaglutide could theoretically launch sooner, but no manufacturer has filed an abbreviated biologics license application (aBLA) as of April 2026.

The only near-term price pressure comes from compounded semaglutide, which remains legal under FDA policy while brand-name shortages persist. This is the single largest cost arbitrage in the obesity medication market.

Insurance coverage: the prior authorization maze

Wegovy is covered by approximately 68% of commercial insurance plans as of 2026, according to data from IQVIA. Coverage does not mean automatic approval. Nearly all plans require prior authorization (PA), which involves:

Standard prior authorization criteria (most plans):

• BMI ≥ 30, or BMI ≥ 27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea)
• Documentation of failed attempts at diet and exercise (typically 3 to 6 months)
• No contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2)
• Prescriber attestation that the patient will receive behavioral counseling

Step therapy requirements (30% of plans):

• Trial of metformin or phentermine for 90 days with documented failure or intolerance
• Some plans require trial of liraglutide (Saxenda) before approving Wegovy

Quantity limits:

• Most plans limit to one pen per week (four pens per 28 days)
• Some plans require dose escalation documentation before approving maintenance doses

The PA approval rate is roughly 60% on first submission. Denials are most often due to insufficient documentation of prior weight-loss attempts or missing comorbidity codes. Appeals succeed about 40% of the time when resubmitted with complete documentation.

Processing time averages 3 to 7 business days for standard PA, 24 to 48 hours for urgent PA (rare for weight-loss medications). Some plans have implemented "gold card" programs that waive PA for endocrinologists and obesity medicine specialists with high approval rates.

What FormBlends sees in prior authorization patterns: The single most common denial reason in our provider network is "insufficient trial of lifestyle modification." Plans want to see documented weights, diet logs, or exercise records over 90+ days. A single office note saying "patient tried diet and exercise" gets denied. Three months of MyFitnessPal exports or weekly weigh-in logs get approved. The documentation burden is the real barrier, not the clinical criteria.

The Wegovy Savings Card: who qualifies and who doesn't

The Wegovy Savings Card, offered directly by Novo Nordisk, is the most significant out-of-pocket cost reducer for eligible patients. It works as a copay assistance program, covering the gap between your insurance copay and a capped maximum.

How it works:

• You pay as little as $0 per month (if your insurance copay is low)
• Maximum savings: $500 per 28-day prescription
• Annual maximum benefit: $6,000 (covers 12 months at maximum savings)
• Resets each calendar year

Eligibility requirements:

• Must have commercial (private) insurance that covers Wegovy
• Insurance must process the claim first; the card applies to remaining copay
• Cannot be used if you're paying full cash price (no insurance claim)
• U.S. residency required

Excluded populations (cannot use the savings card):

• Medicare Part D enrollees (federal anti-kickback statute)
• Medicaid enrollees (federal law)
• Tricare or other federal healthcare programs
• Uninsured patients paying cash
• Patients whose insurance denies coverage entirely

The savings card is activated at WegovySavingsCard.com. You receive a physical card or digital card number that you present to the pharmacy along with your insurance card. The pharmacy processes the insurance claim first, then applies the savings card to reduce your copay.

Real-world example:

• Insurance copay: $400 per month (tier 3 specialty)
• Wegovy Savings Card applied: covers $400, reducing your cost to $0
• If copay were $600, card covers $500, you pay $100

The card does NOT work if your insurance denies the claim. You must have an approved prior authorization and active coverage for the card to apply.

What most articles get wrong about "free Wegovy"

The phrase "free Wegovy" appears in dozens of blog posts and patient forums, creating a dangerous misconception. Here's the error: most articles conflate "eligible for the savings card" with "will pay $0."

The misconception: "If you have insurance, Wegovy is free with the savings card."

The reality: You pay $0 only if your insurance copay is $500 or less AND you qualify for the savings card. If your plan doesn't cover Wegovy at all, the card is worthless. If you're on Medicare, the card is illegal to use.

A 2024 analysis by the Kaiser Family Foundation found that 23% of commercially insured patients who attempted to fill Wegovy prescriptions were denied coverage entirely, prior authorization failed, or their plan excluded obesity medications from the formulary. For those patients, the savings card provides zero benefit because there's no insurance claim to apply it to.

The second error: articles claim the savings card "makes Wegovy affordable for everyone." This ignores the 65 million Americans on Medicare (who cannot use it) and the 85 million on Medicaid (most of whom cannot use it). The savings card helps roughly 30% to 40% of Wegovy-seeking patients. The majority either pay full price, go without, or turn to compounded alternatives.

The third error: failing to mention the annual cap. The $6,000 annual maximum sounds generous until you realize it covers exactly 12 months at the $500/month maximum savings level. If you need Wegovy for 18 or 24 months (the typical treatment duration in clinical trials), you'll hit the cap and revert to full copay for months 13 onward unless the benefit resets.

This matters because the clinical data shows that weight regain begins within 8 to 12 weeks of stopping semaglutide (Wilding et al., Diabetes Obesity and Metabolism 2022). Patients who can afford only 12 months of treatment often regain 60% to 80% of lost weight within a year of stopping.

The compounded semaglutide alternative: same molecule, different price

Compounded semaglutide is the identical active pharmaceutical ingredient as Wegovy, prepared by a licensed compounding pharmacy in response to an individual prescription. It costs $249 to $399 per month through telehealth platforms, an 81% to 70% discount compared to brand-name pricing.

How compounded semaglutide is legal: The FDA allows compounding pharmacies to produce medications that are in shortage under Section 503A of the Federal Food, Drug, and Cosmetic Act. Semaglutide has been on the FDA drug shortage list continuously since March 2022 (for Ozempic) and since May 2023 (for Wegovy). As long as the shortage persists, compounded versions remain legal.

What you get:

• Semaglutide base powder reconstituted in bacteriostatic water or saline
• Supplied in multi-dose vials (typically 2 mg, 5 mg, or 10 mg per vial)
• Patient draws doses using insulin syringes (same subcutaneous injection technique as Wegovy pens)
• Dosing follows the same escalation schedule as brand-name Wegovy (0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg)

What you don't get:

• FDA approval or batch testing (compounded medications are not FDA-approved)
• Pre-filled pens (you draw your own dose)
• The Novo Nordisk brand name or packaging
• Insurance coverage (compounded medications are almost never covered)

Pricing structure (FormBlends and comparable platforms):

• Initial consultation: $49 to $99 (one-time)
• Monthly medication cost: $249 to $399 depending on dose
• Shipping: included
• Supplies (syringes, alcohol swabs): included or $15/month

The total first-month cost is typically $298 to $498 (consultation + medication). Subsequent months are $249 to $399. Over 12 months, the total cost is $3,037 to $4,887, compared to $16,188 for brand-name Wegovy at list price.

Quality and safety considerations: Compounded semaglutide is prepared by state-licensed 503A pharmacies, which are subject to state board of pharmacy inspections but not FDA manufacturing oversight. The FormBlends pharmacy network uses USP-grade semaglutide base powder and follows USP 797 sterile compounding standards. Third-party testing for potency and sterility is performed on every batch, though this is not federally required.

The risk profile is comparable to other compounded injectables. The main risks are dosing errors (if the patient miscalculates), contamination (if sterile technique is not followed), or underdosing (if the compounded product is less potent than labeled). These risks are minimized through patient education, pre-filled dosing charts, and batch testing.

The decision tree: brand vs compounded for your situation

Use this decision framework to determine whether brand-name Wegovy or compounded semaglutide makes sense for your situation.

Choose brand-name Wegovy if:

• Your insurance covers it with prior authorization AND your copay with the savings card is $0 to $100/month → Brand is cheaper and easier
• You are uncomfortable drawing your own doses from a vial → Pens are more convenient
• You want FDA-approved medication only → Compounded products are not FDA-approved
• You have a high deductible plan but will hit your out-of-pocket max anyway → Brand counts toward deductible; compounded does not

Choose compounded semaglutide if:

• Your insurance denies coverage or you're uninsured → Compounded is 70% to 85% cheaper than cash-pay brand
• You're on Medicare or Medicaid → Brand is not covered; compounded is your only option under $1,000/month
• Your copay even with the savings card exceeds $250/month → Compounded is cheaper
• You're comfortable with injections and want the lowest cost option → Compounded wins on price

The gray zone (either option works):

• Your insurance copay with savings card is $100 to $250/month → Brand and compounded cost about the same; choose based on convenience preference
• You're planning 6 months of treatment or less → Upfront cost matters more than long-term formulary risk; either works
• You want to start immediately and insurance PA is delayed → Start with compounded, switch to brand when PA clears

When neither option works:

• You cannot afford $250+/month → Explore clinical trials, patient assistance programs, or behavioral weight-loss programs
• You have contraindications (MTC history, MEN2) → Semaglutide is contraindicated regardless of source
• You're pregnant or breastfeeding → GLP-1 agonists are not recommended

The most common pattern we see: patients start with compounded semaglutide while waiting for insurance PA to process (3 to 8 weeks), then switch to brand-name Wegovy if the PA is approved and the copay is lower. About 40% stay on compounded because the price difference outweighs the convenience of pens.

Medicare and Medicaid: why coverage remains blocked

Medicare Part D is prohibited by federal law from covering medications prescribed for weight loss. This stems from the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, which explicitly excludes "drugs used for weight loss or weight gain" from Part D formularies.

The exclusion applies even though Wegovy is FDA-approved and clinically effective. The law does not distinguish between effective and ineffective weight-loss drugs. It categorically excludes the indication.

The loophole that doesn't work: Some patients ask whether Wegovy can be covered if prescribed "off-label" for diabetes. The answer is no for two reasons:

1. Wegovy is FDA-approved only for obesity, not diabetes. Medicare Part D covers FDA-approved indications, and obesity is excluded.
2. If a provider prescribes semaglutide for diabetes, the correct drug is Ozempic (approved for diabetes), not Wegovy. Ozempic IS covered by Medicare Part D, but at diabetes doses (0.5 mg to 2 mg weekly), not obesity doses (2.4 mg weekly).

Prescribing Wegovy and coding it as diabetes treatment is insurance fraud and exposes both the provider and patient to legal risk.

Medicaid coverage (state-by-state): Medicaid is state-administered, so coverage varies. As of April 2026, 12 states cover Wegovy under their Medicaid formularies:

• California, Colorado, Connecticut, Delaware, Louisiana, Maine, Massachusetts, New York, Oregon, Vermont, Virginia, Washington

Coverage in these states requires prior authorization and is typically limited to patients with BMI ≥ 35 or BMI ≥ 30 with comorbidities. The remaining 38 states plus D.C. do not cover Wegovy under Medicaid.

Legislative outlook: The Treat and Reduce Obesity Act (TROA) has been introduced in Congress every session since 2013. It would eliminate the Medicare Part D exclusion for obesity medications. As of April 2026, it has 80 co-sponsors in the House and 12 in the Senate but has not advanced to a floor vote. Political analysts estimate less than 20% probability of passage in the current session.

Even if TROA passes, it would not take effect until the following fiscal year, and CMS would need 12 to 18 months to issue coverage guidance. Realistically, Medicare coverage for Wegovy is unlikely before 2028.

For the 65 million Medicare beneficiaries, the options are:

1. Pay $1,349/month out of pocket for brand-name Wegovy (unaffordable for most)
2. Use compounded semaglutide at $249 to $399/month
3. Go without

The out-of-pocket calculation worksheet

Use this worksheet to calculate your true monthly cost for Wegovy:

Step 1: Determine your insurance status

• [ ] I have commercial insurance → Go to Step 2
• [ ] I have Medicare → Your cost is $1,349/month (brand) or $249 to $399/month (compounded)
• [ ] I have Medicaid → Check your state list above; if not covered, cost is $1,349/month (brand) or $249 to $399/month (compounded)
• [ ] I am uninsured → Your cost is $1,349/month (brand) or $249 to $399/month (compounded)

Step 2: Check if your plan covers Wegovy

• Call the number on your insurance card and ask: "Is Wegovy (semaglutide for obesity) on my formulary?"
• [ ] Yes, it's covered → Go to Step 3
• [ ] No, it's excluded → Your cost is $1,349/month (brand) or $249 to $399/month (compounded)

Step 3: Determine your formulary tier

• Ask: "What tier is Wegovy on, and what is my copay?"
• Tier 1 (generic): Rare; copay $10 to $30
• Tier 2 (preferred brand): Uncommon; copay $50 to $150
• Tier 3 (non-preferred brand): Most common; copay $150 to $550
• Tier 4 (specialty): Some plans; copay 20% to 40% of cost ($270 to $540)

Step 4: Apply the Wegovy Savings Card

• If your copay is ≤ $500, the card reduces it to $0
• If your copay is $501 to $1,000, the card reduces it by $500 (you pay the remainder)
• Example: $400 copay → $0 after card. $700 copay → $200 after card.

Step 5: Calculate annual cost

• Monthly cost × 12 = annual cost
• Compare to compounded semaglutide: $249 to $399/month × 12 = $2,988 to $4,788/year

Example calculation:

• Commercial insurance, tier 3, $300 copay
• Wegovy Savings Card applied: $300 - $300 = $0/month
• Annual cost: $0 (until you hit the $6,000 annual savings cap, which you won't at $0/month)
• Conclusion: Brand-name Wegovy is the better option

Example calculation 2:

• Commercial insurance, tier 4, $500 copay
• Wegovy Savings Card applied: $500 - $500 = $0/month
• Annual cost: $0
• Conclusion: Brand-name Wegovy is the better option

Example calculation 3:

• Medicare Part D (no coverage)
• Cash price: $1,349/month
• Annual cost: $16,188
• Compounded alternative: $299/month = $3,588/year
• Conclusion: Compounded semaglutide saves $12,600/year

When brand-name Wegovy is worth the premium

There are specific situations where paying more for brand-name Wegovy makes clinical or practical sense, even if compounded semaglutide is cheaper.

1. You have a high-deductible health plan and will hit your out-of-pocket max. If your plan has a $5,000 deductible and $8,000 out-of-pocket max, and you're planning surgery or have other major medical expenses, brand-name Wegovy counts toward those limits. Compounded semaglutide does not. Once you hit your out-of-pocket max, Wegovy becomes free for the rest of the year.

2. You have severe needle anxiety or dexterity issues. Wegovy pens are pre-filled, single-dose, and require only pressing a button. Compounded semaglutide requires drawing the correct dose from a vial using an insulin syringe, which involves more steps and higher risk of dosing error. For patients with arthritis, vision impairment, or severe injection anxiety, pens are meaningfully easier.

3. You're traveling frequently or have inconsistent refrigeration access. Wegovy pens are stable at room temperature for up to 28 days after first use. Compounded semaglutide vials must be refrigerated continuously. If you travel for work, live in a van, or have unreliable power, pens are more practical.

4. You want the clinical trial formulation exactly. The STEP trials used Novo Nordisk's proprietary semaglutide formulation with specific excipients and pH buffering. Compounded semaglutide uses the same active ingredient but different inactive ingredients. For patients who want to replicate the exact trial conditions (for peace of mind or because they're risk-averse), brand is the only option.

5. Your employer offers a zero-copay obesity benefit. A small but growing number of employers (about 8% as of 2026, per the National Business Group on Health) offer fully-covered obesity medications as part of wellness programs. If your employer covers Wegovy at $0 copay, there's no financial reason to choose compounded.

6. You're participating in a clinical outcome study. Some employers, insurers, or research institutions offer free or subsidized Wegovy in exchange for participation in real-world evidence studies. If you're enrolled in one of these programs, brand is provided at no cost.

In all other situations, compounded semaglutide offers equivalent clinical outcomes at a fraction of the cost. The active ingredient is identical, the dosing is identical, and the mechanism of action is identical. The difference is convenience, packaging, and FDA oversight, not efficacy.

The 2026 shortage landscape and what it means for access

Semaglutide has been on the FDA drug shortage list since March 2022 (Ozempic) and May 2023 (Wegovy). As of April 2026, both remain in shortage, though the situation has improved compared to 2023.

Current shortage status (FDA data as of April 2026):

• Ozempic 0.25 mg/0.5 mg pens: Available
• Ozempic 1 mg pens: Available
• Ozempic 2 mg pens: Intermittent availability
• Wegovy 0.25 mg pens: Available
• Wegovy 0.5 mg pens: Available
• Wegovy 1 mg pens: Intermittent availability
• Wegovy 1.7 mg pens: Limited availability
• Wegovy 2.4 mg pens: Limited availability

"Intermittent availability" means pharmacies can order the product but may experience backorders lasting 2 to 6 weeks. "Limited availability" means Novo Nordisk is rationing supply to existing patients and not accepting new starts at that dose.

What this means for patients:

• Starting Wegovy is easier in 2026 than it was in 2023 or 2024. Most patients can access starter doses (0.25 mg and 0.5 mg) without delay.
• Escalating to maintenance doses (1.7 mg and 2.4 mg) may require waiting or switching pharmacies.
• Some patients are "stuck" at 1 mg because higher doses are unavailable. This is suboptimal (clinical trials show maximum efficacy at 2.4 mg) but better than no treatment.

Why the shortage persists: Novo Nordisk has invested $6 billion in manufacturing expansion since 2022, adding three new production lines in Denmark, North Carolina, and France. Despite this, demand growth has outpaced supply growth. The company reported in its Q4 2025 earnings call that semaglutide demand grew 47% year-over-year, while production capacity grew 38%.

The bottleneck is not the active ingredient (semaglutide powder is relatively easy to synthesize). It's the fill-finish process for the pens, which requires specialized aseptic manufacturing lines and has a 24-month lead time from novel to production.

Implications for compounded semaglutide: As long as the FDA shortage list includes any semaglutide product, compounding pharmacies can legally produce semaglutide under 503A. The FDA has stated it will not take enforcement action against compounders while the shortage persists.

If Novo Nordisk resolves the shortage and the FDA removes semaglutide from the shortage list, compounding pharmacies would have 60 days to cease production. This is unlikely before late 2026 or early 2027 based on current manufacturing timelines.

For patients choosing between brand and compounded, the shortage creates a decision point: start with compounded now (guaranteed availability), or wait for brand-name PA approval (possible backorder delays). Most clinicians recommend starting with whichever option is available immediately, since every month of delay is a month of continued obesity-related health risk.

FAQ

How much does Wegovy cost per month? Wegovy costs $1,349.02 per month at list price without insurance. With commercial insurance and prior authorization, most patients pay $25 to $550 copays. The Wegovy Savings Card can reduce this to $0 to $225 for eligible patients. Compounded semaglutide costs $249 to $399 per month.

Is Wegovy available in pill form? No. Wegovy is only available as a subcutaneous injection in pre-filled pens. The confusion stems from Rybelsus, which is oral semaglutide approved for diabetes (not weight loss) at lower doses. Rybelsus is not interchangeable with Wegovy.

Does insurance cover Wegovy? About 68% of commercial insurance plans cover Wegovy with prior authorization. Medicare Part D does not cover it due to federal law. Medicaid coverage varies by state, with 12 states covering it as of 2026. Most plans require documentation of BMI ≥ 30 or BMI ≥ 27 with comorbidities.

Can I use the Wegovy Savings Card if I'm on Medicare? No. Federal anti-kickback laws prohibit manufacturer copay cards for Medicare and Medicaid beneficiaries. The savings card is only available to patients with commercial insurance.

How much is compounded semaglutide compared to Wegovy? Compounded semaglutide costs $249 to $399 per month, which is 70% to 81% less than Wegovy's $1,349 list price. Over 12 months, compounded costs $2,988 to $4,788 vs $16,188 for brand-name Wegovy at full price.

Is compounded semaglutide the same as Wegovy? Compounded semaglutide contains the same active ingredient (semaglutide) at the same doses as Wegovy. It is not FDA-approved and is prepared by compounding pharmacies rather than manufactured by Novo Nordisk. The clinical effect is equivalent, but packaging and quality oversight differ.

Why is Wegovy so expensive? Wegovy's price reflects development costs (over $800 million in clinical trials), comparator pricing (similar to other obesity medications), and Novo Nordisk's market positioning. The company has stated it will not reduce pricing while demand exceeds supply. Generic competition is not expected until 2031 to 2033.

Will Wegovy prices go down in 2026? Unlikely. Novo Nordisk held list prices flat from 2024 through early 2026 but has not announced any reductions. Prices typically decrease only when generic competition enters the market, which is not expected for semaglutide until patents expire in the early 2030s.

How do I get Wegovy for free? "Free" Wegovy is only possible if you have commercial insurance with low copays and qualify for the Wegovy Savings Card, which can reduce your out-of-pocket cost to $0. This applies to roughly 30% to 40% of patients. Medicare, Medicaid, and uninsured patients cannot access free Wegovy through the savings card.

What if my insurance denies Wegovy? If your insurance denies coverage, you can appeal the decision with documentation of BMI, comorbidities, and prior weight-loss attempts. If the appeal fails, your options are paying $1,349/month for brand-name Wegovy, switching to compounded semaglutide at $249 to $399/month, or exploring other weight-loss medications.

Can I switch from Wegovy to compounded semaglutide? Yes. The active ingredient and dosing are identical, so you can switch at the same dose without re-titrating. Most patients switch to save money once they've established that semaglutide works for them. The main difference is using a vial and syringe instead of a pen.

How long do I need to take Wegovy? Clinical trials show that weight loss plateaus at 60 to 68 weeks of treatment. Stopping semaglutide results in weight regain, with most patients regaining 60% to 80% of lost weight within 12 months. Current clinical guidance suggests indefinite treatment for sustained weight loss, similar to other chronic disease medications.

Does Wegovy work better than compounded semaglutide? No. The active ingredient is identical, so clinical efficacy is equivalent. The STEP trials used brand-name semaglutide, but the mechanism of action depends on the molecule, not the manufacturer. Compounded semaglutide produces the same weight loss, same side effect profile, and same metabolic benefits.

What is the cheapest way to get semaglutide for weight loss? Compounded semaglutide through a telehealth platform is the cheapest option for most patients, costing $249 to $399/month. For patients with excellent insurance and access to the Wegovy Savings Card, brand-name Wegovy can cost $0 to $100/month, which is cheaper than compounded. Check your specific insurance situation using the worksheet above.

Are there patient assistance programs for Wegovy? Novo Nordisk offers a patient assistance program (PAP) for uninsured patients with household income below 400% of the federal poverty level (about $60,000 for an individual). The program provides free Wegovy for up to 12 months. Applications are processed through NovoCare at 1-888-668-6444.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
4. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obesity and Metabolism. 2022.
5. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
6. Novo Nordisk. Wegovy Prescribing Information. 2021 (updated 2024).
7. U.S. Food and Drug Administration. Drug Shortages Database. Accessed April 2026.
8. IQVIA Institute for Human Data Science. Obesity Medication Access and Affordability Report. 2025.
9. Kaiser Family Foundation. Medicare Part D Coverage of Weight Loss Medications. 2024.
10. National Business Group on Health. Large Employers' Health Care Strategy and Plan Design Survey. 2025.
11. American College of Gastroenterology. Obesity Management Guidelines. 2022.
12. Centers for Medicare and Medicaid Services. Medicaid State Drug Utilization Data. 2025.
13. U.S. Congress. Treat and Reduce Obesity Act (H.R. 1577 / S. 596). 2025.
14. Novo Nordisk Q4 2025 Earnings Call Transcript. February 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. Saxenda is a registered trademark of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or any other pharmaceutical manufacturer.